Peri-transplant insulin therapy in pancreas transplantation
Research type
Research Study
Full title
"Peri-transplAnt InsuliN Therapy to improve outcomes after pancrEas tRansplantation (PAINTER): an open label randomised clinical trial"
IRAS ID
248520
Contact name
Iestyn Shapey
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Pancreas transplantation is the treatment of choice for patients with complex diabetes. We have demonstrated that poor blood sugar control during the transplant procedure and for the first five days thereafter is associated with higher rates of failure. We don’t know whether this is because the donated pancreas may take a little while to function optimally, or because of the stress that the pancreas experiences during the donation and transplantation process, or because poor blood sugar control compounds both of these effects. Insulin offers a treatment for all of these causes and effects, and we hope to determine whether good blood sugar control with insulin improves transplant outcomes. It is standard practice for pancreas transplant recipients to have, when required, an insulin drip before and during transplantation, but this is ceased when the sugar level drops below a certain reading. We want to test a different type of plan for the insulin drip which is continued for the first five days after transplantation, where the dose is specifically tailored to each individual to provide better blood sugar control. A similar approach is routinely used for all of our islet cell transplant recipients, but we need to demonstrate its safety and feasibility for solid pancreas transplant recipients as well before proceeding to a full trial.
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
18/NW/0778
Date of REC Opinion
11 Dec 2018
REC opinion
Further Information Favourable Opinion